{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:24:46Z","timestamp":1767824686033,"version":"3.49.0"},"reference-count":10,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":2650,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><jats:p>A recent study by Morgan and colleagues found that cannabidiol attenuates the acute cognitive effects of delta-9-tetrahydrocannabinol (THC). This is of interest as THC has been associated with the detrimental effects of cannabis on mental health in at-risk users, and the potency of cannabis is increasing across Europe.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.bp.110.081380","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T18:22:44Z","timestamp":1285870964000},"page":"259-260","source":"Crossref","is-referenced-by-count":10,"title":["Does cannabidiol protect against the negative effects of THC?"],"prefix":"10.1192","volume":"197","author":[{"given":"C\u00e9cile","family":"Henquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kuepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S000712500025304X_ref4","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br J Psychiatry"},{"key":"S000712500025304X_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(00)00201-X"},{"key":"S000712500025304X_ref8","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2006000400001"},{"key":"S000712500025304X_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(09)70440-7"},{"key":"S000712500025304X_ref10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.072249"},{"key":"S000712500025304X_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1556-4029.2007.00603.x"},{"key":"S000712500025304X_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707442"},{"key":"S000712500025304X_ref3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.064220"},{"key":"S000712500025304X_ref5","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"S000712500025304X_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.077503"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000712500025304X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T17:28:01Z","timestamp":1556386081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000712500025304X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S000712500025304X"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.110.081380","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}